Impact of Total Intravenous Anesthesia Following Cancer Surgery, TIVACS Study
Status:
Not yet recruiting
Trial end date:
2024-12-31
Target enrollment:
Participant gender:
Summary
This phase II trials studies the impact of total intravenous anesthesia (TIVA) following
cancer surgery. Surgery and the anesthesia delivered causes physiologic stress and trauma
resulting in immune suppression. TIVA is an alternative method of general anesthesia that has
several benefits over volatile inhalation agents such as reducing nausea, vomiting, and
opioid consumption, and promotes earlier return of bowel function following surgery. In
addition, TIVA is less immunosuppressive than inhalational agents and has been shown to
decrease cancer cell proliferation, migration, and metastasis formation. Giving TIVA during
cancer-directed abdominal surgery may decrease the immunosuppressive state in the
peri-surgical period.